Generic Drugs Market 2025-2035

Description

List of Tables

Generic Drugs Market Size, Share & Trends Analysis Report, By Application (Cancer, CVD, Musculoskeletal Diseases, Infectious Diseases, Neurology, Diabetes, and Others), By Route of Administration (Oral, Topical, Injectable, and Inhaler), Forecast Period (2025-2035)

Industry Overview

Generic drugs market was valued at $411.7 billion in 2024 and is projected to reach $720.6 billion by 2035, growing at a CAGR of 5.3% during the forecast period (2025-2035). The global generic drugs market is experiencing notable growth, driven by increasing demand for cost-effective treatment options across multiple therapeutic areas. Expanding patient populations and rising prevalence of chronic diseases are compelling healthcare providers to adopt affordable medication alternatives. Pharmaceutical companies are investing in advanced manufacturing and regulatory-compliant formulations to meet this demand. Additionally, government initiatives promoting accessibility and insurance coverage for generics are supporting wider adoption. The development of high-quality, clinically validated products further reinforces market confidence.

Market Dynamics

Rising Adoption of Oncology Generic Drugs

The global demand for generic oncology drugs is witnessing steady growth due to increasing cancer prevalence and the need for cost-effective therapies. Companies like Teva Pharmaceutical Industries Ltd. are expanding their portfolio of generic anticancer medications to improve patient accessibility. Advanced manufacturing capabilities and robust R&D pipelines are enabling faster approvals and market penetration. Healthcare providers are favoring generics to reduce treatment costs without compromising efficacy. Regulatory support in multiple regions further accelerates adoption. This trend is expected to sustain, driven by both emerging and developed markets.

Growth in Oral and Injectable Formulations

Oral and injectable generic drugs remain the dominant segments globally, offering convenience and improved patient adherence. Sandoz International GmbH has been actively developing generic injectables for cardiovascular and neurological conditions. Technological advancements in formulation and bioequivalence studies are facilitating smoother regulatory approvals. Increasing chronic disease prevalence, such as diabetes and cardiovascular disorders, is boosting demand for these formulations. Market players are focusing on portfolio diversification to meet regional needs. The trend reflects a shift toward patient-centric, accessible treatment options.

Market Segmentation

Based on the route of administration, the market is segmented into oral, topical, injectable, and inhaler.
Based on the application, the market is segmented into cancer, CVD, musculoskeletal diseases, infectious diseases, neurology, diabetes, and others.

Cardiovascular Disease (CVD) Segment to Lead the Market with the Largest Share

The global generic drugs market is witnessing steady expansion driven by increased demand for cardiovascular disease (CVD) therapies. The rising prevalence of heart-related conditions has prompted pharmaceutical companies to focus on cost-effective treatment solutions. For instance, Teva Pharmaceutical Industries Ltd. has introduced a range of generic CVD medications to cater to this growing patient population. Enhanced awareness campaigns and government initiatives to promote affordable healthcare are further stimulating market uptake. The availability of clinically approved generics with proven efficacy is also encouraging widespread adoption. Collectively, these factors are sustaining robust growth in the CVD segment.

Oral is a Key Segment in Generic Drug Market Growth

Oral formulations continue to dominate the global generic drugs market due to their convenience and patient compliance. Companies such as Mylan N.V. have developed an extensive portfolio of orally administered generics, ranging from tablets to capsules, to address various therapeutic areas. The preference for oral medications is reinforced by their ease of distribution and lower production costs. Moreover, growing awareness of preventive healthcare and chronic disease management is increasing oral drug consumption. Regulatory approvals for bioequivalent formulations are facilitating wider market access. Consequently, oral generics are emerging as a key driver of global market growth.

Regional Outlook

The global generic drugs market is further divided by geography, including North America (the US and Canada), Europe (the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, Australia and New Zealand, ASEAN Countries, and the Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

Increasing Focus on Cost Containment and Improved Patient Care in Europe

The European generic drugs market is expanding as healthcare systems focus on cost containment and improved patient access. Sandoz International GmbH has been instrumental in supplying high-quality generic alternatives across multiple therapeutic areas. Favorable policies, such as reimbursement schemes for generics and streamlined approval processes, are encouraging adoption. The increasing incidence of chronic illnesses among aging populations is also driving demand. The presence of robust manufacturing infrastructure and consistent regulatory oversight ensures reliability and safety. These combined factors are contributing to steady growth in the European generics landscape.

North America Region Dominates the Market with a Major Share

In North America, the generic drugs market is growing owing to the rising burden of chronic diseases and emphasis on affordable treatment. Companies such as Pfizer Inc. are actively expanding their generic drug offerings, particularly in therapeutic segments like oncology and cardiovascular care. Strong healthcare insurance frameworks and government incentives for generics are accelerating patient access. The trend toward substituting branded drugs with cost-effective generics is increasingly evident. Additionally, technological advancements in formulation and quality control support widespread adoption. Together, these dynamics are driving sustained market growth in the region.

Market Players Outlook

The major companies operating in the global generic drugs market include Dr. Reddy's Laboratories Ltd., Sandoz (a Novartis division), Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Viatris Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

In August 2025, Teva Pharmaceuticals, Inc., a US affiliate of Teva Pharmaceutical Industries Ltd., announced the FDA approval and US launch of a generic version of Saxenda1 (liraglutide injection). Generic Saxenda is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the US market. This approval and launch add to Teva's continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy.
In August 2025, Lupin Ltd. announced the launch of Bosentan Tablets for Oral Suspension, 32 mg, in the US. This follows the approval received by Lupin's alliance partner, NATCO Pharma Ltd. (NATCO), for its Abbreviated New Drug Application from the US Food and Drug Administration (U.S. FDA). NATCO holds the exclusive first-to-file status for this product and will have 180-day generic drug exclusivity.
In January 2024, Amneal Pharmaceuticals, Inc. announced that it had launched 39 new retail and injectable medicines in 2023, as compared to 26 new launches in 2022. In the fourth quarter of 2023, Amneal launched 13 new products, including 5 injectables. New injectable products added include potassium phosphate vials, tranexamic acid, and esmolol intravenous bags. These launches provide a strong foundation for higher injectable revenues going forward.

The Report Covers:

Market value data analysis of 2024 and forecast to 2035.
Annualized market revenues ($ million) for each market segment.
Country-wise analysis of major geographical regions.
Key companies operating in the global generic drugs market. Based on the availability of data, information related to new products and relevant news is also available in the report.
Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
Analysis of market-entry and market expansion strategies.
Competitive strategies by identifying 'who-stands-where' in the market.

Product Code: OMR2023545

1. Report Summary

Current Industry Analysis and Growth Potential Outlook
Global Generic Drugs Market Sales Analysis - Route of Administration | Application | ($ Million)
Generic Drugs Market Sales Performance of Top Countries
1.1. Research Methodology
Primary Research Approach
Secondary Research Approach
1.2. Market Snapshot

2. Market Overview and Insights

2.1. Scope of the Study
2.2. Analyst Insight & Current Market Trends
- 2.2.1. Key Generic Drugs Market Trends
- 2.2.2. Market Recommendations
2.3. Porter's Five Forces Analysis for the Generic Drugs Market
- 2.3.1. Competitive Rivalry
- 2.3.2. Threat of New Entrants
- 2.3.3. Bargaining Power of Suppliers
- 2.3.4. Bargaining Power of Buyers
- 2.3.5. Threat of Substitutes

3. Market Determinants

3.1. Market Drivers
- 3.1.1. Drivers For Global Generic Drugs Market: Impact Analysis
3.2. Market Pain Points and Challenges
- 3.2.1. Restraints For Global Generic Drugs Market: Impact Analysis
3.3. Market Opportunities

4. Competitive Landscape

4.1. Competitive Dashboard - Generic Drugs Market Revenue and Share by Manufacturers
Generic Drugs Product Comparison Analysis
Top Market Player Ranking Matrix
4.2. Key Company Analysis
- 4.2.1. Dr. Reddy's Laboratories Ltd.
  - 4.2.1.1. Overview
  - 4.2.1.2. Product Portfolio
  - 4.2.1.3. Financial Analysis (Subject to Data Availability)
  - 4.2.1.4. SWOT Analysis
  - 4.2.1.5. Business Strategy
- 4.2.2. Sandoz (a Novartis division)
  - 4.2.2.1. Overview
  - 4.2.2.2. Product Portfolio
  - 4.2.2.3. Financial Analysis (Subject to Data Availability)
  - 4.2.2.4. SWOT Analysis
  - 4.2.2.5. Business Strategy
- 4.2.3. Sun Pharmaceutical Industries Ltd.
  - 4.2.3.1. Overview
  - 4.2.3.2. Product Portfolio
  - 4.2.3.3. Financial Analysis (Subject to Data Availability)
  - 4.2.3.4. SWOT Analysis
  - 4.2.3.5. Business Strategy
- 4.2.4. Teva Pharmaceutical Industries Ltd.
  - 4.2.4.1. Overview
  - 4.2.4.2. Product Portfolio
  - 4.2.4.3. Financial Analysis (Subject to Data Availability)
  - 4.2.4.4. SWOT Analysis
  - 4.2.4.5. Business Strategy
- 4.2.5. Viatris Inc.
  - 4.2.5.1. Overview
  - 4.2.5.2. Product Portfolio
  - 4.2.5.3. Financial Analysis (Subject to Data Availability)
  - 4.2.5.4. SWOT Analysis
  - 4.2.5.5. Business Strategy
4.3. Top Winning Strategies by Market Players
- 4.3.1. Merger and Acquisition
- 4.3.2. Product Launch
- 4.3.3. Partnership And Collaboration

5. Global Generic Drugs Market Sales Analysis by Route of Administration ($ Million)

5.1. Oral
5.2. Topical
5.3. Injectable
5.4. Inhaler

6. Global Generic Drugs Market Sales Analysis by Application ($ Million)

6.1. Cancer
6.2. CVD
6.3. Musculoskeletal Diseases
6.4. Infectious Diseases
6.5. Neurology
6.6. Diabetes
6.7. Others

7. Regional Analysis

7.1. North American Generic Drugs Market Sales Analysis - Route of Administration | Application | Country ($ Million)
Macroeconomic Factors for North America
- 7.1.1. United States
- 7.1.2. Canada
7.2. European Generic Drugs Market Sales Analysis - Route of Administration | Application | Country ($ Million)
Macroeconomic Factors for Europe
- 7.2.1. UK
- 7.2.2. Germany
- 7.2.3. Italy
- 7.2.4. Spain
- 7.2.5. France
- 7.2.6. Russia
- 7.2.7. Rest of Europe
7.3. Asia-Pacific Generic Drugs Market Sales Analysis - Route of Administration | Application | Country ($ Million)
Macroeconomic Factors for Asia-Pacific
- 7.3.1. China
- 7.3.2. Japan
- 7.3.3. South Korea
- 7.3.4. India
- 7.3.5. Australia & New Zealand
- 7.3.6. ASEAN Countries (Thailand, Indonesia, Vietnam, Singapore, And Other)
- 7.3.7. Rest of Asia-Pacific
7.4. Rest of the World Generic Drugs Market Sales Analysis - Route of Administration | Application | Country ($ Million)
Macroeconomic Factors for Rest of the World
- 7.4.1. Latin America
- 7.4.2. Middle East and Africa

8. Company Profiles

8.1. Alembic Pharmaceuticals Ltd.
- 8.1.1. Quick Facts
- 8.1.2. Company Overview
- 8.1.3. Product Portfolio
- 8.1.4. Business Strategies
8.2. Apotex Inc.
- 8.2.1. Quick Facts
- 8.2.2. Company Overview
- 8.2.3. Product Portfolio
- 8.2.4. Business Strategies
8.3. Aurobindo Pharma Ltd.
- 8.3.1. Quick Facts
- 8.3.2. Company Overview
- 8.3.3. Product Portfolio
- 8.3.4. Business Strategies
8.4. Biocon Ltd.
- 8.4.1. Quick Facts
- 8.4.2. Company Overview
- 8.4.3. Product Portfolio
- 8.4.4. Business Strategies
8.5. Cadila Healthcare Ltd.
- 8.5.1. Quick Facts
- 8.5.2. Company Overview
- 8.5.3. Product Portfolio
- 8.5.4. Business Strategies
8.6. Cipla Ltd.
- 8.6.1. Quick Facts
- 8.6.2. Company Overview
- 8.6.3. Product Portfolio
- 8.6.4. Business Strategies
8.7. Dr. Reddy's Laboratories Ltd.
- 8.7.1. Quick Facts
- 8.7.2. Company Overview
- 8.7.3. Product Portfolio
- 8.7.4. Business Strategies
8.8. Fresenius Kabi AG
- 8.8.1. Quick Facts
- 8.8.2. Company Overview
- 8.8.3. Product Portfolio
- 8.8.4. Business Strategies
8.9. Glenmark Pharmaceuticals Ltd.
- 8.9.1. Quick Facts
- 8.9.2. Company Overview
- 8.9.3. Product Portfolio
- 8.9.4. Business Strategies
8.10. Hikma Pharmaceuticals
- 8.10.1. Quick Facts
- 8.10.2. Company Overview
- 8.10.3. Product Portfolio
- 8.10.4. Business Strategies
8.11. Lupin Pharmaceuticals
- 8.11.1. Quick Facts
- 8.11.2. Company Overview
- 8.11.3. Product Portfolio
- 8.11.4. Business Strategies
8.12. Mylan (now part of Viatris)
- 8.12.1. Quick Facts
- 8.12.2. Company Overview
- 8.12.3. Product Portfolio
- 8.12.4. Business Strategies
8.13. Sandoz (a Novartis division)
- 8.13.1. Quick Facts
- 8.13.2. Company Overview
- 8.13.3. Product Portfolio
- 8.13.4. Business Strategies
8.14. Stada Arzneimittel AG
- 8.14.1. Quick Facts
- 8.14.2. Company Overview
- 8.14.3. Product Portfolio
- 8.14.4. Business Strategies
8.15. Sun Pharmaceutical Industries Ltd.
- 8.15.1. Quick Facts
- 8.15.2. Company Overview
- 8.15.3. Product Portfolio
- 8.15.4. Business Strategies
8.16. Sunovion Pharmaceuticals Inc.
- 8.16.1. Quick Facts
- 8.16.2. Company Overview
- 8.16.3. Product Portfolio
- 8.16.4. Business Strategies
8.17. Teva Pharmaceutical Industries Ltd.
- 8.17.1. Quick Facts
- 8.17.2. Company Overview
- 8.17.3. Product Portfolio
- 8.17.4. Business Strategies
8.18. Torrent Pharmaceuticals Ltd.
- 8.18.1. Quick Facts
- 8.18.2. Company Overview
- 8.18.3. Product Portfolio
- 8.18.4. Business Strategies
8.19. Viatris Inc.
- 8.19.1. Quick Facts
- 8.19.2. Company Overview
- 8.19.3. Product Portfolio
- 8.19.4. Business Strategies
8.20. Zydus Lifesciences Ltd.
- 8.20.1. Quick Facts
- 8.20.2. Company Overview
- 8.20.3. Product Portfolio
- 8.20.4. Business Strategies